Letrozol Bluefish

Letrozole, the active ingredient in Letrozol Bluefish, is an aromatase inhibitor presented as an oral tablet for oral use. It is employed to treat hormone‑receptor positive breast cancer in postmenopausal women, both in advanced disease and as adjuvant therapy. It is formulated for once‑daily oral administration and is indicated for both metastatic and early‑stage disease management.

GNH USA supplies Letrozol Bluefish as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres, hospitals and pharmacies worldwide, ensuring quality‑assured batches and reliable logistics.

Letrozole acts on estrogen‑dependent breast cancer pathways and is indicated for the following clinical situations:

Hormone‑receptor positive metastatic breast cancer (postmenopausal): Reduces estrogen levels to slow tumor progression. Adjuvant therapy for early‑stage hormone‑receptor positive breast cancer (postmenopausal): Decreases risk of disease recurrence after surgery. Neoadjuvant treatment in postmenopausal patients: Lowers tumor size before definitive surgery. Extended adjuvant therapy after initial treatment: Provides continued estrogen suppression to maintain disease‑free status.

Letrozole may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Hot flashes: Sudden feeling of warmth, often with sweating. - Joint and muscle pain: Arthralgia or myalgia affecting daily activities. - Fatigue: Persistent tiredness not relieved by rest. - Nausea: Mild to moderate upset stomach. - Headache: Tension‑type or throbbing pain.

Serious or Rare Side Effects: - Severe liver injury: Elevated transaminases or hepatitis requiring discontinuation. - Deep vein thrombosis or pulmonary embolism: Blood clots in veins or lungs. - Osteoporotic fractures: Reduced bone mineral density leading to fractures. - Anaphylactic reaction: Rapid onset of swelling, hives, or breathing difficulty.

When prescribing letrozole, clinicians should observe several precautionary measures to ensure patient safety. - Pregnancy contraindication: Must not be used in pregnant women; teratogenic risk (Category X). - Breastfeeding restriction: Discontinue if patient is nursing; drug may pass into milk. - Bone health monitoring: Assess bone mineral density periodically and consider calcium/vitamin D supplementation. - Liver function assessment: Perform baseline and periodic liver enzyme tests. - Drug hypersensitivity: Avoid in patients with known allergy to letrozole or other aromatase inhibitors. - Drug interactions: Review concomitant medications for CYP3A4 modulators. - Store at ambient temperature: Keep below 25 °C in original packaging, protect from moisture.

Letrozole’s metabolism and pharmacodynamics can be altered by several co‑administered medicines.

Major Interactions (Avoid): - Tamoxifen: Antagonistic effect reduces letrozole efficacy. - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): Decrease plasma concentrations, compromising treatment. - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): Increase exposure, raising risk of toxicity.

Moderate Interactions (Monitor Closely): - Warfarin: May enhance anticoagulant effect, requiring INR monitoring. - Selective serotonin reuptake inhibitors (e.g., paroxetine): Potentially affect metabolism, monitor for side effects. - Statins (e.g., simvastatin): May increase risk of hepatic enzyme elevation, monitor liver function.